Stockscreener 앱 받기
3.20
4.48%
-0.15
시간 외 거래:
3.45
0.25
+7.81%
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Post-Trade Analysis: Corvus Pharmaceuticals Inc (CRVS) Slides -6.03, Closing at 3.35 - DWinneX
Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com
CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel
Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com
Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX
Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News
Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune
Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times
Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - The Manila Times
Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com
Corvus Pharmaceuticals expands board with new director - Investing.com Australia
Corvus Pharmaceuticals Appoints New Director to Board - TipRanks
Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN
Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada
Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - Greenwich Time
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq
CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter
Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times
0.60%
2.05%
자본화:
|
볼륨(24시간):